BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 21321192)

  • 1. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Nadji M; Szepeshazi K; Zarandi M; Vidaurre I; Perez R; Halmos G; Szalontay L
    Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3755-60. PubMed ID: 21321192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Abi-Chaker A; Krishan A; Szalontay L
    Prostate; 2013 Jun; 73(8):873-83. PubMed ID: 23280565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonists of growth hormone-releasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells.
    Siejka A; Schally AV; Block NL; Barabutis N
    Prostate; 2010 Jul; 70(10):1087-93. PubMed ID: 20232355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonists of growth hormone-releasing hormone inhibit proliferation induced by inflammation in prostatic epithelial cells.
    Popovics P; Schally AV; Salgueiro L; Kovacs K; Rick FG
    Proc Natl Acad Sci U S A; 2017 Feb; 114(6):1359-1364. PubMed ID: 28123062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
    Rick FG; Szalontay L; Schally AV; Block NL; Nadji M; Szepeshazi K; Vidaurre I; Zarandi M; Kovacs M; Rekasi Z
    J Urol; 2012 Apr; 187(4):1498-504. PubMed ID: 22341819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers.
    Perez R; Schally AV; Vidaurre I; Rincon R; Block NL; Rick FG
    Oncotarget; 2012 Sep; 3(9):988-97. PubMed ID: 22941871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
    Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM
    Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of GHRH antagonists on human glioblastomas and their mechanism of action.
    Pozsgai E; Schally AV; Zarandi M; Varga JL; Vidaurre I; Bellyei S
    Int J Cancer; 2010 Nov; 127(10):2313-22. PubMed ID: 20162575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.
    Szalontay L; Schally AV; Popovics P; Vidaurre I; Krishan A; Zarandi M; Cai RZ; Klukovits A; Block NL; Rick FG
    Cell Cycle; 2014; 13(17):2790-7. PubMed ID: 25486366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway.
    Guo J; Schally AV; Zarandi M; Varga J; Leung PC
    Reprod Biol Endocrinol; 2010 May; 8():54. PubMed ID: 20509930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases.
    Rick FG; Schally AV; Szalontay L; Block NL; Szepeshazi K; Nadji M; Zarandi M; Hohla F; Buchholz S; Seitz S
    Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1655-60. PubMed ID: 22307626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist.
    Rick FG; Abi-Chaker A; Szalontay L; Perez R; Jaszberenyi M; Jayakumar AR; Shamaladevi N; Szepeshazi K; Vidaurre I; Halmos G; Krishan A; Block NL; Schally AV
    Proc Natl Acad Sci U S A; 2013 Feb; 110(7):2617-22. PubMed ID: 23359692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.
    Zhao L; Yano T; Osuga Y; Nakagawa S; Oishi H; Wada-Hiraike O; Tang X; Yano N; Kugu K; Schally AV; Taketani Y
    Int J Oncol; 2008 Mar; 32(3):593-601. PubMed ID: 18292936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone-releasing hormone antagonists reduce prostatic enlargement and inflammation in carrageenan-induced chronic prostatitis.
    Popovics P; Cai R; Sha W; Rick FG; Schally AV
    Prostate; 2018 Sep; 78(13):970-980. PubMed ID: 29786867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
    Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
    Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel.
    Hohla F; Schally AV; Szepeshazi K; Varga JL; Buchholz S; Köster F; Heinrich E; Halmos G; Rick FG; Kannadka C; Datz C; Kanashiro CA
    Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14513-8. PubMed ID: 16983095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer.
    Halmos G; Schally AV; Czompoly T; Krupa M; Varga JL; Rekasi Z
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4707-14. PubMed ID: 12364462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models.
    Muñoz-Moreno L; Arenas MI; Carmena MJ; Schally AV; Prieto JC; Bajo AM
    Invest New Drugs; 2014 Oct; 32(5):871-82. PubMed ID: 25000999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
    Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
    Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antinflammatory, antioxidant, and behavioral effects induced by administration of growth hormone-releasing hormone analogs in mice.
    Recinella L; Chiavaroli A; Orlando G; Ferrante C; Marconi GD; Gesmundo I; Granata R; Cai R; Sha W; Schally AV; Brunetti L; Leone S
    Sci Rep; 2020 Jan; 10(1):732. PubMed ID: 31959947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.